Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Peripheral T-cell Lymphoma
Latest Information Update: 16 Jun 2024
At a glance
- Drugs Pralatrexate (Primary) ; Romidepsin (Primary)
- Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2024 Results reporting safety and efficacy data from phase 2 portion of this trial published in the Leukemia and Lymphoma
- 06 Feb 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 06 Feb 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.